Cargando…
Regdanvimab: First Approval
Regdanvimab (Regkirona™) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc. for the treatment of coronavirus disease 2019 (COVID-19). In September 2021, regdanvimab received full approval in South K...
Autor principal: | Syed, Yahiya Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558754/ https://www.ncbi.nlm.nih.gov/pubmed/34724174 http://dx.doi.org/10.1007/s40265-021-01626-7 |
Ejemplares similares
-
Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022) -
Sparsentan: First Approval
por: Syed, Yahiya Y.
Publicado: (2023) -
Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017) -
Sacituzumab Govitecan: First Approval
por: Syed, Yahiya Y.
Publicado: (2020) -
Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)